AbirateroneAcetate , 10mMinDMSO , 154229-18-2
Synonym(s):
17-(Pyridin-3-yl)androsta-5,16-dien-3β-yl acetate;Abiraterone acetate;CB 7598
CAS NO.：154229-18-2
Empirical Formula: C26H33NO2
Molecular Weight: 391.55
MDL number: MFCD00934213
EINECS: 620-314-7
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 127-130°C |
| Boiling point: | 506.7±50.0 °C(Predicted) |
| Density | 1.14±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | Chloroform (Slightly), DMSO (Sparingly), Methanol (Sparingly) |
| pka | 5.31±0.12(Predicted) |
| form | powder |
| color | white to beige |
| InChIKey | UVIQSJCZCSLXRZ-UBUQANBQSA-N |
| SMILES | C1[C@@]2(C)C(=CC[C@]3([H])[C@]2([H])CC[C@]2(C)C(C4=CC=CN=C4)=CC[C@@]32[H])C[C@@H](OC(=O)C)C1 |
Description and Uses
In April 2011, the United States FDA approved abiraterone acetate (CB7630) in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. Abiraterone acetate affects prostate, testicular, and adrenal androgens by irreversibly inhibiting both the lyase and hydroxylase activity of cytochrome P450 17A (CYP17) signaling pathways (IC50's of 2.9 and 4 nM, respectively) thereby decreasing testosterone levels.Most common serious adverse events for abiraterone acetate versus placebo included fluid retention (30.5% vs. 22.3%), hypokalemia (17.1% vs. 8.4%), hypertension (9.7% vs. 7.9%), hepatic transaminase abnormalities (10.4% vs. 8.1%), and cardiac abnormalities (13.3% vs. 10.4%).
A novel steroidal inhibitor of human Cytochrome P450(17a-Hydroxylase-C17,20-lyase): potential agent for the treatment of prostatic cancer.
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Danger |
| Hazard statements | H360-H372 |
| Precautionary statements | P201-P202-P260-P264-P270-P308+P313 |
| WGK Germany | 3 |
| RTECS | BV7992100 |
| HS Code | 2937290000 |
